for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AstraZeneca plc

AZN.L

現在値

10,712.00GBp

変化

206.00(+1.96%)

出来高

1,141,949

本日のレンジ

10,512.00

 - 

10,740.00

52週レンジ

8,029.00

 - 

11,289.62

∙ 約20分前の相場を表示しています。

適時開示

Lynparza Receives Health Canada Approval As Adjuvant Treatment For Patients With Germline Brca-Mutated Her2-Negative High-Risk Early Breast Cancer

Aug 11 (Reuters) - AstraZeneca PLC <AZN.L>::LYNPARZA RECEIVES HEALTH CANADA APPROVAL AS ADJUVANT TREATMENT FOR PATIENTS WITH GERMLINE BRCA-MUTATED HER2-NEGATIVE HIGH-RISK EARLY BREAST CANCER.

FDA Approved Enhertu, IV Infusion For Treatment Of Patients With Unresectable Or Metastatic Her2-Low Breast Cancer

Aug 5 (Reuters) - FDA::FDA SAYS APPROVED ENHERTU, IV INFUSION FOR TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC HER2-LOW BREAST CANCER.FDA SAYS PRESCRIBING INFO FOR ENHERTU INCLUDES BOXED WARNING TO ADVISE HEALTH CARE PROFESSIONALS OF RISK OF INTERSTITIAL LUNG DISEASE & EMBRYO-FETAL TOXICITY.FDA SAYS ENHERTU IS NOT RECOMMENDED FOR WOMEN WHO ARE PREGNANT.Further company coverage: 4568.T. ((Reuters.Briefs@thomsonreuters.com;)).

AstraZeneca Says Calquence Tablet Formulation Approved In US Across Current Indications

Aug 5 (Reuters) - AstraZeneca PLC <AZN.L>::CALQUENCE TABLET FORMULATION APPROVED IN THE US ACROSS CURRENT INDICATIONS.ASTRAZENECA - NEW FORMULATION CAN BE CO-ADMINISTERED WITH GASTRIC ACID-REDUCING AGENTS.ASTRAZENECA - TABLET OFFERS EQUIVALENT EFFICACY, SAFETY AND CONSISTENT DOSING COMPARED TO CURRENT CAPSULE.ASTRAZENECA - IN ELEVATE-PLUS TRIALS, RESULTS SHOWED CALQUENCE CAPSULE AND TABLET FORMULATIONS ARE BIOEQUIVALENT.

EMA Publishes Assessment Report For Vaxzevria Supporting Introduction Of Its Booster Dose

Aug 4 (Reuters) - European Medicines Agency: :EMA: EMA PUBLISHED THE ASSESSMENT REPORT FOR VAXZEVRIA SUPPORTING THE INTRODUCTION OF ITS BOOSTER DOSE: 04/08/2022. ((Reuters.Briefs@thomsonreuters.com;)).

Innate Pharma: AstraZeneca Will Discontinue INTERLINK-1 Phase 3 Study

Aug 1 (Reuters) - Innate Pharma SA <IPH.PA>::INNATE PHARMA PROVIDES UPDATE ON ASTRAZENECA-SPONSORED INTERLINK-1 PHASE 3 STUDY.FUTILITY INTERIM ANALYSIS OF INTERLINK-1 PHASE 3 STUDY SPONSORED BY ASTRAZENECA DID NOT MEET A PRE-DEFINED THRESHOLD FOR EFFICACY.ASTRAZENECA HAS INFORMED INNATE THAT STUDY WILL BE DISCONTINUED.THERE WERE NO NEW SAFETY FINDINGS. ASTRAZENECA PLAN TO SHARE DATA IN DUE COURSE..

AstraZeneca Appoints Michel Demaré As Chair-Designate Of Board

July 29 (Reuters) - AstraZeneca PLC <AZN.L>::ASTRAZENECA PLC - CHAIR SUCCESSION.ASTRAZENECA - APPOINTMENT OF MICHEL DEMARÉ AS CHAIR-DESIGNATE OF BOARD..ASTRAZENECA - LEIF JOHANSSON, CURRENT CHAIR OF BOARD OF ASTRAZENECA WILL BE RETIRING AT CONCLUSION OF COMPANY'S ANNUAL GENERAL MEETING IN APRIL 2023.

Astrazeneca Says FY Total Revenue Expected To Increase By Low Twenties Percentage

July 29 (Reuters) - AstraZeneca PLC <AZN.L>::HALF-YEAR REPORT.HY REPORTED EPS $0.48.HY CORE EPS $3.61.HY TOTAL REVENUE $22,161 MLN VS $15,540 MLN AS REPORTED LAST YEAR.FY TOTAL REVENUE IS EXPECTED TO INCREASE BY A LOW TWENTIES PERCENTAGE (PREVIOUSLY HIGH TEENS).CER GROWTH RATES GUIDANCE INCLUDE FULL-YEAR CONTRIBUTION OF VAXZEVRIA IN BOTH FY 2021 AND FY 2022.FY TOTAL REVENUE FROM COVID-19 MEDICINES IS ANTICIPATED TO BE BROADLY FLAT VERSUS FY 2021.FY 2022 EXPECTATION FOR CORE TAX RATE REMAINS 18-22%.INTERIM DIVIDEND DECLARED OF $0.93 PER ORDINARY SHARE.CONTINUES TO RECOGNISE & ACTIVELY MANAGE HEIGHTENED RISKS FROM COVID-19 & GEOPOLITICAL AND SUPPLY CHAIN UNCERTAINTIES ON OVERALL BUSINESS.IN CHINA, COVID-19 RELATED LOCKDOWNS IN SEVERAL MAJOR CITIES HAD AN ADVERSE IMPACT DURING Q2 IN ONCOLOGY.GROUP'S CURRENT FOCUS IS TO CONTINUE COMPLIANT BUSINESS OPERATIONS IN RUSSIA AND UKRAINE.

EMA Says Product Information Of Vaxzevria To Be Updated With Tinnitus, New Side Effects

July 14 (Reuters) - European Medicines Agency: :EMA SAYS PRODUCT INFORMATION OF NUVAXOVID WILL BE UPDATED WITH SEVERE ALLERGIC REACTION, UNUSUAL OR DECREASED FEELING IN SKIN AS NEW SIDE EFFECTS.EMA SAYS PRODUCT INFORMATION OF VAXZEVRIA WILL BE UPDATED WITH TINNITUS AND UNUSUAL OR DECREASED FEELING IN THE SKIN AS NEW SIDE EFFECTS.EMA- EXTENSIVE SWELLING OF THE VACCINATED LIMB WILL BE INCLUDED IN THE EU PRODUCT INFORMATION AS A SIDE EFFECT OF SPIKEVAX.Further company coverage: NVAX.O. ((Reuters.Briefs@thomsonreuters.com;)).

Astrazeneca To Acquire Teneotwo And T Cell Engager

July 5 (Reuters) - AstraZeneca PLC <AZN.L>::ASTRAZENECA PLC - ASTRAZENECA TO ACQUIRE TENEOTWO AND T CELL ENGAGER.TNB-486 WILL BE EVALUATED IN MULTIPLE TYPES OF LYMPHOMA.WILL ACQUIRE ALL OUTSTANDING EQUITY OF TENEOTWO IN EXCHANGE FOR AN UPFRONT PAYMENT OF $100M ON DEAL CLOSING .ACQUISITION OF TNB-486 AIMS TO ACCELERATE DEVELOPMENT OF THIS POTENTIAL NEW MEDICINE FOR B-CELL HAEMATOLOGIC MALIGNANCIES.ASTRAZENECA WILL ACQUIRE ALL OUTSTANDING EQUITY OF TENEOTWO IN EXCHANGE FOR AN UPFRONT PAYMENT OF $100M ON DEAL CLOSING.TRANSACTION IS EXPECTED TO CLOSE IN Q3 OF 2022.TRANSACTION DOES NOT IMPACT ASTRAZENECA'S FINANCIAL GUIDANCE FOR 2022.ASTRAZENECA WILL MAKE ADDITIONAL CONTINGENT R&D-RELATED MILESTONE PAYMENTS OF UP TO $805M.ASTRAZENECA WILL MAKE ADDITIONAL CONTINGENT COMMERCIAL-RELATED MILESTONE PAYMENTS OF UP TO $360M TO TENEOTWO'S EQUITY HOLDERS.TRANSACTION WILL BE ACCOUNTED FOR AS AN INTANGIBLE ASSET ACQUISITION.

AstraZeneca Says Results From Positive Focus Phase III Trial In Wilson Disease Showed That ALXN1840 Met Its Primary Endpoint

June 23 (Reuters) - AstraZeneca PLC <AZN.L>::ASTRAZENECA - FOCUS PHASE III TRIAL EVALUATES NEW APPROACH TO COPPER MOBILISATION FOR PATIENTS WITH WILSON DISEASE.ASTRAZENECA - DETAILED RESULTS FROM POSITIVE FOCUS PHASE III TRIAL IN WILSON DISEASE SHOWED THAT ALXN1840 MET ITS PRIMARY ENDPOINT.ASTRAZENECA - IN TRIAL, PEOPLE TAKING ALXN1840 EXPERIENCED RAPID COPPER MOBILISATION, WITH A RESPONSE AT FOUR WEEKS AND SUSTAINED THROUGH 48 WEEKS.ASTRAZENECA - ALXN1840 WAS WELL TOLERATED AND LONG-TERM SAFETY AND EFFICACY OF ALXN1840 IS BEING ASSESSED IN AN UP TO 60-MONTH EXTENSION PERIOD.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up